Sustained release of a p38 inhibitor from non-inflammatory microspheres inhibits cardiac dysfunction.
Sustained release of a p38 inhibitor from non-inflammatory microspheres inhibits cardiac dysfunction.
复制标题
作者：
急性心肌梗死后的心功能不全是世界范围内死亡的主要原因，迫切需要新的治疗策略。在这份报告中，我们证明了直接心脏注射的载药微粒，配制从聚合物聚（环己烷-1，4-二基丙酮二亚甲基缩酮）（PCADK），改善心肌梗死后的心脏功能。药物递送载体具有通过在受损心肌内维持高浓度的治疗剂来改善心功能障碍的治疗的巨大潜力。PCADK在目前用于药物递送的聚合物中是独特的，因为其水解产生中性降解产物。我们在这里表明，PCADK引起最小的组织炎症反应，从而使PCADK用于治疗炎症性疾病，如心功能不全。PCADK具有治疗心肌梗死和其他炎症性疾病的巨大希望，因为其中性、生物相容性降解产物及其提供广泛治疗的能力。
Cardiac dysfunction following acute myocardial infarction is a major cause of death in the world and there is a compelling need for new therapeutic strategies. In this report we demonstrate that a direct cardiac injection of drug-loaded microparticles, formulated from the polymer poly(cyclohexane-1,4-diylacetone dimethylene ketal) (PCADK), improves cardiac function following myocardial infarction. Drug-delivery vehicles have great potential to improve the treatment of cardiac dysfunction by sustaining high concentrations of therapeutics within the damaged myocardium. PCADK is unique among currently used polymers in drug delivery in that its hydrolysis generates neutral degradation products. We show here that PCADK causes minimal tissue inflammatory response, thus enabling PCADK for the treatment of inflammatory diseases, such as cardiac dysfunction. PCADK holds great promise for treating myocardial infarction and other inflammatory diseases given its neutral, biocompatible degradation products and its ability to deliver a wide range of therapeutics.
登录
查看更多内容
影响因子：
4.7
作者：
Lee, Sungmun;Yang, Stephen C.;Murthy, Niren
通讯作者：
Murthy, Niren
影响因子：
5.5
作者：
Fink, B;Laude, K;Dikalov, S
通讯作者：
Dikalov, S
影响因子：
24
作者：
See, F;Thomas, W;Krum, H
通讯作者：
Krum, H
DOI：
10.1152/ajpheart.00043.2006
发表时间：
2006-10-01
影响因子：
4.8
作者：
Li, Zhihe;Ma, Jing Ying;Protter, Andrew A.
通讯作者：
Protter, Andrew A.
影响因子：
3.3
作者：
Porras, A;Zuluaga, S;Nebreda, AR
通讯作者：
Nebreda, AR